Nobu Trading’s Innovative Health Products for Babies, Kids, and Adults to Debut at ECRM’s ‘Vitamin, Weight Management & Sports Nutrition Program’
September 09, 2021 13:21 ET
|
NOBU TRADING LTD
PALM BEACH, FL, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Nobu Trading’s popular healthcare product lines for babies, children, and adults will debut in America this month at ECRM’s “Vitamin, Weight...
Nobu Trading Plans U.S. Launch of its Innovative Health Products for Babies, Kids, and Adults
August 02, 2021 12:17 ET
|
NOBU TRADING LTD
PALM BEACH, FL, Aug. 02, 2021 (GLOBE NEWSWIRE) -- This week, London-based Nobu Trading announced plans to export its popular healthcare product lines for babies, children, and adults to America. ...
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
July 14, 2021 09:00 ET
|
Auris Medical AG
Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs....
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
June 28, 2021 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Inhalation & Nasal Spray Generic Drugs Market at CAGR of 8.29% by 2031: Visiongain Research Inc.
June 17, 2021 12:30 ET
|
Visiongain Ltd
Visiongain has published a new report on Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031. Profiles of Inhalation & Nasal Spray Generic Drugs and Forecasts By Drug Class...
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
June 01, 2021 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
April 13, 2021 07:45 ET
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
January 29, 2021 08:30 ET
|
Auris Medical AG
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
December 01, 2020 09:00 ET
|
Auris Medical AG
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
November 20, 2020 09:10 ET
|
Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...